Schalm S W, Heytink R A, Van Buuren H R, De Man R A
J Hepatol. 1986;3 Suppl 2:S189-92. doi: 10.1016/s0168-8278(86)80119-2.
Patients with chronic hepatitis B and active viral replication had no change in DNA-polymerase (DNA-p) and HBeAg when treated with weekly injections of lymphoblastoid alpha-interferon (IFN) for 4-10 weeks. Daily IFN (2.5 MU/m2 for a period of 4 weeks) was associated with a significant fall (P less than 0.05) in DNA-p but not in HBeAg; DNA-p remained or became negative in 3 out of 10 patients after stopping therapy. Combination of IFN and intravenous acyclovir (ACV, 15 mg/kg twice daily) led to a significantly greater fall in DNA-p and HBeAg, while tolerance of the combination therapy was excellent. Four out of 5 patients became DNA-p-negative and three HBeAg-negative; subsequently two became HBsAg-negative with anti-HBs. We conclude that weekly IFN appears ineffective. Daily IFN depressed hepatitis B virus replication, but does not change markedly the natural course of the disease. Combination therapy with ACV may be more effective than IFN alone and is well tolerated.
慢性乙型肝炎且病毒活跃复制的患者，接受每周注射淋巴母细胞α干扰素（IFN）治疗4至10周后，其DNA聚合酶（DNA-p）和HBeAg无变化。每日注射IFN（2.5 MU/m²，持续4周）会使DNA-p显著下降（P<0.05），但HBeAg无变化；10名患者中有3名在停止治疗后DNA-p保持阴性或转为阴性。IFN与静脉注射阿昔洛韦（ACV，15 mg/kg，每日两次）联合使用，可使DNA-p和HBeAg下降幅度显著增大，且联合治疗的耐受性良好。5名患者中有4名DNA-p转为阴性，3名HBeAg转为阴性；随后有2名患者HBsAg转为阴性并产生抗-HBs。我们得出结论，每周注射IFN似乎无效。每日注射IFN可抑制乙型肝炎病毒复制，但不会显著改变疾病的自然病程。ACV联合治疗可能比单独使用IFN更有效，且耐受性良好。
